NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Albert Einstein College of Medicine
Conditions: Acid Sphingomyelinase Deficiency, Ceroid Lipofuscinosis, Neuronal, 2, Cerebrotendinous Xanthomatosis, Fabry Disease, GM1 Gangliosidosis
Interventions: Confirmatory Testing
Countries: United States
ScreenPlus is a consented, multi-disorder pilot newborn screening program implemented in conjunction with the New York State Newborn Screening Program that provides families the option to have their newborn(s) screened for a panel of additional conditions. The study has three primary objectives: 1) define the analytic and clinical validity of multi-tiered screening assays for a flexible panel of disorders, 2) determine disease incidence in a large newborn population, and 3) assess the impact of early diagnosis on health outcomes. Over a nine-year period, ScreenPlus aims to screen 100,000 infants born in eight high birthrate hospitals in New York for a flexible panel of rare genetic disorders. This study will also evaluate the Ethical, Legal and Social issues pertaining to NBS for complex disorders, which will be done via online surveys that will be directed towards ScreenPlus parents who opt to participate and qualitative interviews with families of infants who are identified through ScreenPlus.
Sex: ALL
Age: — to 4 Weeks
Healthy volunteers: Yes
Study type: OBSERVATIONAL
Inclusion Criteria: * All newborn infants born at a ScreenPlus pilot hospital * Infants who are less than four weeks old, regardless of sex, gestational age, or health status. Exclusion Criteria: * A newborn screening sample is unavailable * Infants who are more than four weeks old
- Brooklyn, New York, United States
- Brooklyn, New York, United States
- Manhasset, New York, United States
- New York, New York, United States
- New York, New York, United States
- New York, New York, United States
- Queens, New York, United States
- The Bronx, New York, United States
- The Bronx, New York, United States